Skip to main content
. 2017 May 23;6(6):1240–1254. doi: 10.1002/cam4.1083

Figure 5.

Figure 5

SM/Chol liposomal topotecan exhibits improved therapeutic activity compared to two‐times the dose of Hycamtin. The antitumor activity of topotecan was assessed against the s.c. (panels A and B) and systemic (panels C and D) LAN‐1 neuroblastoma models following administration of SM/Chol liposomal topotecan (5 mg/kg) or Hycamtin (10 mg/kg) where the drug was administered intravenously on day 14, 21 and 28 (arrows). Kaplan–Meier survival plots (A, C) and median survival times (B, D) are shown. Survival curves were determined based on when the mice reached a humane endpoint as defined in the Methods. The day of death was recorded 1 day following euthanasia. The efficacy studies were completed using groups of 8 mice per dose tested. Although an increase in mean survival time by using SM/Chol liposomal topotecan, the differences with Hycamtin treatment in both models were not statistically significant by the log‐rank test, P > 0.05.